Ventricular antitachycardia pacing therapy in XXXX with heart failure implanted with a cardiac resynchronization therapy defibrillator device: Efficacy, safety, and impact on mortality.

@entity1 @entity1165 @entity1163 @entity955 @entity943
BACKGROUND: Cardiac resynchronization therapy defibrillator can terminate @entity1165 ( @entity1165 ) and @entity1165 ( @entity1165 ) via antitachycardia pacing (ATP). OBJECTIVES: We evaluated efficacy and safety of ATP, whether ATP induces @entity943 after inappropriate ATP or @entity955 ( @entity955 ) after appropriate ATP, and whether ATP is associated with mortality. METHODS: A total of 1404 @entity1 with a cardiac resynchronization therapy defibrillator were followed in a prospective multicenter observational research. All-cause mortality rates were estimated in @entity1 subgroups in order to uncouple the trigger ( @entity1165 / @entity1165 or other rhythms causing inappropriate detections) from ATP therapy. RESULTS: Over a median follow-up of 31 months, 2938 @entity1165 / @entity1165 episodes were treated with ATP in 360 @entity1 . The adjusted ATP success rate was 63% (95% confidence interval [CI] 57%-69%) on FVTs and 68% (95% CI 62%-74%) on VTs. Acceleration occurred in 55 (1.87%) and @entity1163 in 4 (0.14%) of all ATP-treated episodes. In 14 true @entity1165 / @entity1165 episodes in 5 @entity1 , @entity955 followed ATP therapy. In 4 episodes in 2 @entity1 , @entity1165 followed ATP inappropriately applied during @entity955 . Death rate per 100 @entity1 -years was 5.6 (95% CI 4.3-7.5) in @entity1 with appropriate ATP and 1.5 (95% CI 0.4-6.1) in @entity1 with inappropriate ATP (P = .045). CONCLUSION: ATP was effective in terminating @entity1165 / @entity1165 episodes and displayed a good safety profile. ATP therapies by themselves did not increase death risk; prognosis was indeed better in @entity1 without arrhythmic episodes, even if they received inappropriate ATP, than in @entity1 with ATP on @entity1165 / @entity1165 episodes. Adverse outcomes observed in @entity1 receiving implantable cardioverter-defibrillator therapies are probably related to the @entity943 itself, a marker of disease progression, rather than to adverse effects of ATP.
